702 related articles for article (PubMed ID: 25653196)
1. EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line.
Nishimura Y; Takiguchi S; Ito S; Itoh K
Int J Oncol; 2015 Apr; 46(4):1721-9. PubMed ID: 25653196
[TBL] [Abstract][Full Text] [Related]
2. Silencing of SNX1 by siRNA stimulates the ligand-induced endocytosis of EGFR and increases EGFR phosphorylation in gefitinib-resistant human lung cancer cell lines.
Nishimura Y; Takiguchi S; Yoshioka K; Nakabeppu Y; Itoh K
Int J Oncol; 2012 Oct; 41(4):1520-30. PubMed ID: 22859339
[TBL] [Abstract][Full Text] [Related]
3. Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.
Nishimura Y; Takiguchi S; Ito S; Itoh K
Int J Oncol; 2014 Feb; 44(2):412-26. PubMed ID: 24297483
[TBL] [Abstract][Full Text] [Related]
4. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
Nishimura Y; Yoshioka K; Bereczky B; Itoh K
Mol Cancer; 2008 May; 7():42. PubMed ID: 18492291
[TBL] [Abstract][Full Text] [Related]
5. The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines.
Nishimura Y; Bereczky B; Ono M
Histochem Cell Biol; 2007 May; 127(5):541-53. PubMed ID: 17361439
[TBL] [Abstract][Full Text] [Related]
6. Ephedrae herba stimulates hepatocyte growth factor-induced MET endocytosis and downregulation via early/late endocytic pathways in gefitinib-resistant human lung cancer cells.
Nishimura Y; Hyuga S; Takiguchi S; Hyuga M; Itoh K; Hanawa T
Int J Oncol; 2016 May; 48(5):1895-906. PubMed ID: 26983447
[TBL] [Abstract][Full Text] [Related]
7. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
Liu X; Carlisle DL; Swick MC; Gaither-Davis A; Grandis JR; Siegfried JM
Exp Cell Res; 2007 Apr; 313(7):1361-72. PubMed ID: 17349623
[TBL] [Abstract][Full Text] [Related]
8. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
[TBL] [Abstract][Full Text] [Related]
9. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
10. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes.
Dajani OF; Meisdalen K; Guren TK; Aasrum M; Tveteraas IH; Lilleby P; Thoresen GH; Sandnes D; Christoffersen T
J Cell Physiol; 2008 Feb; 214(2):371-80. PubMed ID: 17654493
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
13. A novel role of Rho-kinase in the regulation of ligand-induced phosphorylated EGFR endocytosis via the early/late endocytic pathway in human fibrosarcoma cells.
Nishimura Y; Bereczky B; Yoshioka K; Taniguchi S; Itoh K
J Mol Histol; 2011 Oct; 42(5):427-42. PubMed ID: 21847509
[TBL] [Abstract][Full Text] [Related]
14. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
15. Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway.
Li Y; Huang X; Zhang J; Li Y; Ma K
Int J Biochem Cell Biol; 2013 Nov; 45(11):2349-58. PubMed ID: 23968914
[TBL] [Abstract][Full Text] [Related]
16. Re-localization of activated EGF receptor and its signal transducers to multivesicular compartments downstream of early endosomes in response to EGF.
Oksvold MP; Skarpen E; Wierød L; Paulsen RE; Huitfeldt HS
Eur J Cell Biol; 2001 Apr; 80(4):285-94. PubMed ID: 11370743
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
Choi YJ; Rho JK; Jeon BS; Choi SJ; Park SC; Lee SS; Kim HR; Kim CH; Lee JC
Cancer Chemother Pharmacol; 2010 Jul; 66(2):381-8. PubMed ID: 19921194
[TBL] [Abstract][Full Text] [Related]
18. Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling.
Kharmate G; Rajput PS; Watt HL; Somvanshi RK; Chaudhari N; Qiu X; Kumar U
Biochim Biophys Acta; 2011 Jun; 1813(6):1172-89. PubMed ID: 21419811
[TBL] [Abstract][Full Text] [Related]
19. Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.
Sakai K; Arao T; Shimoyama T; Murofushi K; Sekijima M; Kaji N; Tamura T; Saijo N; Nishio K
FASEB J; 2006 Feb; 20(2):311-3. PubMed ID: 16373402
[TBL] [Abstract][Full Text] [Related]
20. Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs.
Ogi S; Fujita H; Kashihara M; Yamamoto C; Sonoda K; Okamoto I; Nakagawa K; Ohdo S; Tanaka Y; Kuwano M; Ono M
Cancer Sci; 2013 May; 104(5):573-83. PubMed ID: 23360489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
